Venus Medtech (Hangzhou) Past Earnings Performance
Past criteria checks 0/6
Venus Medtech (Hangzhou)'s earnings have been declining at an average annual rate of -42.6%, while the Medical Equipment industry saw earnings growing at 13.7% annually. Revenues have been growing at an average rate of 16.9% per year.
Key information
-42.6%
Earnings growth rate
-34.9%
EPS growth rate
| Medical Equipment Industry Growth | 13.7% |
| Revenue growth rate | 16.9% |
| Return on equity | -37.6% |
| Net Margin | -267.2% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Is Venus Medtech (Hangzhou) (HKG:2500) A Risky Investment?
Oct 05
Is Venus Medtech (Hangzhou) (HKG:2500) Using Debt In A Risky Way?
May 29What Venus Medtech (Hangzhou) Inc.'s (HKG:2500) P/S Is Not Telling You
May 11Time To Worry? Analysts Are Downgrading Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Outlook
Apr 07Is Venus Medtech (Hangzhou) (HKG:2500) Weighed On By Its Debt Load?
Oct 12Need To Know: Analysts Just Made A Substantial Cut To Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Estimates
Sep 04We're Not Very Worried About Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Rate
Jul 28Companies Like Venus Medtech (Hangzhou) (HKG:2500) Are In A Position To Invest In Growth
Mar 29Are Investors Undervaluing Venus Medtech (Hangzhou) Inc. (HKG:2500) By 43%?
Jan 09Here's Why We're Not At All Concerned With Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Situation
Dec 01We're Interested To See How Venus Medtech (Hangzhou) (HKG:2500) Uses Its Cash Hoard To Grow
Aug 16A Look At The Intrinsic Value Of Venus Medtech (Hangzhou) Inc. (HKG:2500)
Jul 12Companies Like Venus Medtech (Hangzhou) (HKG:2500) Can Afford To Invest In Growth
Apr 26Analysts Have Just Cut Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Revenue Estimates By 28%
Apr 05Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares Could Be 23% Above Their Intrinsic Value Estimate
Mar 07What Type Of Shareholders Make Up Venus Medtech (Hangzhou) Inc.'s (HKG:2500) Share Registry?
Feb 14
Venus Medtech (Hangzhou) Inc. (HKG:2500) Is About To Turn The Corner
Jan 19Have Insiders Been Selling Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares?
Dec 29Have Insiders Sold Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares Recently?
Dec 29Can You Imagine How Venus Medtech (Hangzhou)'s (HKG:2500) Shareholders Feel About The 78% Share Price Increase?
Dec 08Revenue & Expenses Breakdown
How Venus Medtech (Hangzhou) makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 452 | -1,208 | 500 | 602 |
| 31 Mar 23 | 429 | -1,133 | 468 | 565 |
| 31 Dec 22 | 406 | -1,058 | 437 | 527 |
| 30 Sep 22 | 397 | -759 | 411 | 451 |
| 30 Jun 22 | 387 | -461 | 382 | 374 |
| 31 Mar 22 | 401 | -417 | 364 | 316 |
| 31 Dec 21 | 416 | -374 | 345 | 258 |
| 30 Sep 21 | 415 | -313 | 320 | 231 |
| 30 Jun 21 | 413 | -252 | 295 | 204 |
| 31 Mar 21 | 345 | -217 | 267 | 186 |
| 31 Dec 20 | 276 | -182 | 239 | 167 |
| 30 Sep 20 | 252 | -210 | 247 | 165 |
| 30 Jun 20 | 228 | -238 | 256 | 163 |
| 31 Mar 20 | 231 | -310 | 289 | 182 |
| 31 Dec 19 | 233 | -381 | 322 | 201 |
| 31 Dec 18 | 115 | -300 | 291 | 105 |
| 31 Dec 17 | 18 | -157 | 56 | 117 |
Quality Earnings: 2500 is currently unprofitable.
Growing Profit Margin: 2500 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2500 is unprofitable, and losses have increased over the past 5 years at a rate of 42.6% per year.
Accelerating Growth: Unable to compare 2500's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2500 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (16%).
Return on Equity
High ROE: 2500 has a negative Return on Equity (-37.59%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/02/19 20:24 |
| End of Day Share Price | 2023/11/22 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Venus Medtech (Hangzhou) Inc. is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wai Chak Yuen | BOCI Research Ltd. |
| Jin Zhang | China International Capital Corporation Limited |
| Haoyuan Zhang | China Merchants Securities (HK) Co., Ltd |